Press Release 2002-2022: DOSIsoft delivering 20 years of Innovation05/04/2022 Epigenetic treatments: New allies for chemotherapies?04/12/2022 Lung cancer: a new treatment combining immunotherapies and chemotherapy reduces risk of recurrence and death by almost 40%04/11/2022 Institut Curie’s key progress for the future of oncology04/08/2022 Biomunex and Institut Curie pursue strategic collaboration for development of disruptive non-conventional T cell redirection approach to treating cancer02/07/2022 Institut Curie equips its surgeons and radiologists with AVATAR MEDICAL’s virtual reality medical image solution11/23/2021 Retinoblastoma: an ambitious project to preserve children’s sight11/16/2021 Institut Curie celebrates the centenary of Marie Curie’s trip to the United States10/28/2021 Egle Therapeutics raises 40 million € Series Ato develop First-In-Class T-regulatory cells therapies based on Treg-starvers10/22/2021 PEP-Therapy and Institut Curie announce first patients dosed in Phase I clinical trial of PEP-010 for the treatment of advanced solid tumors10/05/2021 New startup Aglaia Therapeutics raises €4M in seed funding to overcome resistance in oncology targeted therapies09/27/2021 Research / Breast cancers: ruptures in cell nuclei promotes tumor invasion09/23/2021 Research / FROM YELLOW TO WHITE AND BACK AGAIN: THE SECRET TO THE SPIDER CRAB’S COLOR CHANGES09/06/2021 Prof. Steven Le Gouill, new Director of the Hospital Group at Institut Curie09/01/2021 Accelerating the pace of pediatric oncology research and innovating at Institut Curie, to better care for young patients08/30/2021 Institut Curie applauds the €75 million fundraising achieved by its spin-off Mnemo Therapeutics06/16/2021 Nanomedicine and new targeted therapies: the advances of Institut Curie at the ASCO 2021 Meeting06/07/2021 LEBANON: Institut Curie steps up its support in oncology05/17/2021 “Flash" radiotherapy: another step towards clinical applications for Institut Curie and SIT 05/04/2021 OncoDNA and Institut Curie test the clinical utility of personalized liquid biopsy in head and neck cancers04/16/2021 PEP-Therapy and Institut Curie granted approval from ANSM to start first-in-human clinical trial of PEP-010 for the treatment of advanced solid tumors03/16/2021 Onxeo Enters Clinical Research Agreement with Institut Curie to Conduct a phase 1b/2 Clinical Trial of AsiDNA™ in combination with radiotherapy for Treatment of High-Grade Glioma Relapse in Children02/04/2021 Autoimmune and inflammatory diseases associated with primary immune deficiencies01/21/2021 Keeping Sperm Cells on Track01/19/2021 Covid-19: biological bait in the form of vesicles to stop infection by the SARS-CoV-2 virus01/05/2021 Innovation COVID-19: early results of a large-scale study on the immune response against SARS-CoV-2 conducted with the help of Institut Curie staff12/22/2020 Institut Curie and Google initiate a research collaboration using artificial intelligence (AI) for the analysis of complex transcriptomic and epigenetics data12/22/2020 Intestinal Health : Macrophages lead the conversation between the microbiota and the colon10/19/2020 Cell multiplication : measuring up10/16/2020 Iron-mediated cancer cell activity: a new regulation mechanism08/03/2020 Corporate APPOINTMENT: Alain Puisieux, new director of Institut Curie Research Center09/02/2019 Partnership Institut Curie names Intel lead partner...05/23/2018 Partnership Institut Curie and Pierre Fabre initiate a novel partnership in immuno-oncology 10/20/2017 Partnership Servier and Institut Curie extend duration and scope of partnership09/05/2017
Lung cancer: a new treatment combining immunotherapies and chemotherapy reduces risk of recurrence and death by almost 40%04/11/2022
Biomunex and Institut Curie pursue strategic collaboration for development of disruptive non-conventional T cell redirection approach to treating cancer02/07/2022
Institut Curie equips its surgeons and radiologists with AVATAR MEDICAL’s virtual reality medical image solution11/23/2021
Egle Therapeutics raises 40 million € Series Ato develop First-In-Class T-regulatory cells therapies based on Treg-starvers10/22/2021
PEP-Therapy and Institut Curie announce first patients dosed in Phase I clinical trial of PEP-010 for the treatment of advanced solid tumors10/05/2021
New startup Aglaia Therapeutics raises €4M in seed funding to overcome resistance in oncology targeted therapies09/27/2021
Research / FROM YELLOW TO WHITE AND BACK AGAIN: THE SECRET TO THE SPIDER CRAB’S COLOR CHANGES09/06/2021
Accelerating the pace of pediatric oncology research and innovating at Institut Curie, to better care for young patients08/30/2021
Institut Curie applauds the €75 million fundraising achieved by its spin-off Mnemo Therapeutics06/16/2021
Nanomedicine and new targeted therapies: the advances of Institut Curie at the ASCO 2021 Meeting06/07/2021
“Flash" radiotherapy: another step towards clinical applications for Institut Curie and SIT 05/04/2021
OncoDNA and Institut Curie test the clinical utility of personalized liquid biopsy in head and neck cancers04/16/2021
PEP-Therapy and Institut Curie granted approval from ANSM to start first-in-human clinical trial of PEP-010 for the treatment of advanced solid tumors03/16/2021
Onxeo Enters Clinical Research Agreement with Institut Curie to Conduct a phase 1b/2 Clinical Trial of AsiDNA™ in combination with radiotherapy for Treatment of High-Grade Glioma Relapse in Children02/04/2021
Covid-19: biological bait in the form of vesicles to stop infection by the SARS-CoV-2 virus01/05/2021
Innovation COVID-19: early results of a large-scale study on the immune response against SARS-CoV-2 conducted with the help of Institut Curie staff12/22/2020
Institut Curie and Google initiate a research collaboration using artificial intelligence (AI) for the analysis of complex transcriptomic and epigenetics data12/22/2020
Partnership Institut Curie and Pierre Fabre initiate a novel partnership in immuno-oncology 10/20/2017
